Precision Biosciences Inc
NASDAQ:DTIL
| Market Cap (Intraday) | 41.27M |
| Current PE | 2.61 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $9.94 |
| 50-Day MA | $9.59 |
| 200-Day MA | $11.37 |
Precision Biosciences Inc Stock, NASDAQ:DTIL
Dibrell Building, 302 East Pettigrew Street, Durham, North Carolina 27701
United States of America
Phone: +1.919.314.5512
Number of Employees: 109
Description
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.